NASDAQ:PPH VanEck Pharmaceutical ETF (PPH) Price, Holdings, & News $86.59 -1.58 (-1.79%) (As of 11/15/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHeadlinesHoldingsOptions ChainOwnershipRatingsShort InterestTrends About VanEck Pharmaceutical ETF (NASDAQ:PPH) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get PPH alerts:Sign Up Key Stats Today's Range$86.44▼$87.4050-Day Range$86.59▼$98.3052-Week Range$76.39▼$99.51Volume699,392 shsAverage Volume152,595 shsMarket Capitalization$639.90 millionAssets Under Management$592.30 millionDividend Yield1.85%Net Expense Ratio0.36%Aggregate RatingModerate Buy ETF OverviewThe VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.Read More… War on Elon Escalates… (Ad)A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. VanEck Pharmaceutical ETF ExpensesTypePPHHealth Care ETFsEquity ETFsNASDAQ ETFsAll ETFsManagement Fee0.35%0.57%0.55%0.49%0.52%Other Expenses0.01%0.30%0.49%0.41%0.53%Total Expense0.36%0.70%0.71%0.63%0.71%Fee Waiver0.00%-0.45%-0.52%-0.33%-0.57%Net Expense0.36%0.61%0.61%0.56%0.59% Receive PPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for VanEck Pharmaceutical ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address PPH ETF News HeadlinesThe Zacks Analyst Blog Highlights Eli Lilly, Novo Nordisk, PPH, HRTS and THNROctober 17, 2024 | finance.yahoo.comDiversified Exposure To The Weight Loss Drug MarketOctober 10, 2024 | seekingalpha.comWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.November 17, 2024 | Porter & Company (Ad)Pharma Stocks Losing Ground After A Remarkable Rally, Downgrading PPHOctober 3, 2024 | seekingalpha.comAbbVie stock analysis: Rinvoq and Skyrizi are big catalystsOctober 1, 2024 | msn.comThis Canadian ETF could be a play on the changing fortunes of U.S. Mid-CapsSeptember 20, 2024 | theglobeandmail.comSee More Headlines PPH ETF - Frequently Asked Questions How have PPH shares performed this year? VanEck Pharmaceutical ETF's stock was trading at $81.37 on January 1st, 2024. Since then, PPH shares have increased by 6.4% and is now trading at $86.59. View the best growth stocks for 2024 here. Who are VanEck Pharmaceutical ETF's major shareholders? VanEck Pharmaceutical ETF's top institutional investors include Mirae Asset Global Investments Co. Ltd. (3.23%), Thrivent Financial for Lutherans (3.18%), Miller Investment Management LP (2.81%) and Prime Capital Investment Advisors LLC (1.75%). How do I buy shares of VanEck Pharmaceutical ETF? Shares of PPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of VanEck Pharmaceutical ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that VanEck Pharmaceutical ETF investors own include Waste Connections (WCN), iShares Micro-Cap ETF (IWC), The RMR Group (RMR), DiamondRock Hospitality (DRH), AUO (AUOTY), American Water Works (AWK) and Triple Flag Precious Metals (TFPM). Fund Details IssuerVan Eck Fund NameVanEck Pharmaceutical ETF Tax ClassificationRegulated Investment Company Stock ExchangeNASDAQCurrent SymbolNASDAQ:PPH Inception Date12/20/2011 Fund ManagerHao-Hung Peter Liao, Guo Hua Jason Jin WebN/A Phone14089961010Fund Focus Asset ClassEquity BenchmarkMarket Vectors US Listed Pharmaceutical 25 Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionGlobal Number of Holdings26 Fund Statistics Assets Under Management$592.30 million Average Daily Volume$258,326.80 Discount/Premium-0.03% Administrator, Advisor and Custodian AdministratorVan Eck Associates Corporation AdvisorVan Eck Associates Corporation CustodianState Street Bank and Trust Company DistributorVan Eck Securities Corporation Transfer AgentState Street Bank and Trust Company TrusteeN/A Lead Market MakerIMC Options OptionableOptionable Options Volume1,524 Put Options1,494 Call Options30 Short Interest1,860,000 shs Miscellaneous Outstanding Shares7,390,000Beta0.72 Creation Unit50,000 Creation Fee$500.00 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Top 10 PPH HoldingsEli Lilly and Company (NYSE:LLY)Holding Weight: 13.33%Novo Nordisk A/S (NYSE:NVO)Holding Weight: 8.27%Johnson & Johnson (NYSE:JNJ)Holding Weight: 6.82%AbbVie (NYSE:ABBV)Holding Weight: 6.04%Novartis (NYSE:NVS)Holding Weight: 5.14%Bristol-Myers Squibb (NYSE:BMY)Holding Weight: 5.11%AstraZeneca (NASDAQ:AZN)Holding Weight: 4.97%Merck & Co., Inc. (NYSE:MRK)Holding Weight: 4.91%Zoetis (NYSE:ZTS)Holding Weight: 4.65%Cencora (NYSE:COR)Holding Weight: 4.64%Full Holdings DetailsPPH Sector ExposurePPH Industry Exposure This page (NASDAQ:PPH) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VanEck Pharmaceutical ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share VanEck Pharmaceutical ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
